Drug General Information (ID: DDI5YJXZVB)
Drug Name			Lepirudin		Drug Info		Alemtuzumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antithrombotic Agents				Antineoplastics

Mechanism of Lepirudin-Alemtuzumab Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Lepirudin				Alemtuzumab
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding Antiplatelet/anticoagulant effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Lepirudin and Alemtuzumab

Recommended Action
Management		Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs. Patients should be monitored for increased anticoagulant effects and bleeding complications. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "Canadian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.